ARS Pharmaceuticals IPO

ars-pharma.com

ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.

Founded2015
Total Funding to Date$76.55MM
Register for Details

For more details on financing and valuation for ARS Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

ARS Pharmaceuticals Ticker Symbol

ARS Pharmaceuticals does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

ARS Pharmaceuticals Stock Price

The stock price for ARS Pharmaceuticals will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

ARS Pharmaceuticals Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
8/31/2021 Series D $55MM raised $XXX.XX $XXX.XX
9/14/2018 Series C $20.15MM raised $XXX.XX $XXX.XX
4/30/2018 Series B $1,000K raised $XXX.XX $XXX.XX
4/30/2016 Series A $396.84K raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like ARS Pharmaceuticals in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector